The developments at Holland Capital in 2024 reflect our strong ambitions
Amsterdam/ Düsseldorf, 30th of December 2024 –The developments at Holland Capital in 2024 reflect our strong ambitions. Guided by a focused investment strategy, we continued to actively engage in the high-growth markets of Technology, Healthcare, and Agrifood. Reflecting on a successful year, we completed several key transactions and further strengthened our team.
2024 achievements
- The launch of our fund, Holland Capital Growth and Buy-Out Fund V
- Number of deals in the Netherlands: 5
- Number of add-on acquisitions in the Netherlands: 13
- Number of add-on acquisitions in Germany: 2
- Number of exits: 2
- Number of new colleagues: 4
Sector focus and an entrepreneurial hands-on approach: With specialized sector teams, we focus on the sectors of Healthcare, Technology, and Agrifood, both within the Growth & Buy-out and Venture & Growth segments. We understand the dynamics and opportunities in these sectors and have an extensive network. Holland Capital is not a passive investor; we work closely with management to define and execute strategies. Where needed, our operational team also contributes hands-on to the realization of specific projects within the company.
Which companies would we like to connect with?
- Sector: Technology, Healthcare, and Agrifood
- Positive outlook: Significant growth potential, both autonomous and buy-and-build
- Growth & Buy-out:
- Healthy profitability: cash flow from operations (EBITDA) between EUR 1 – 10m
- Smaller companies: considered as add-on acquisitions for our existing portfolio companies
- Larger companies: considered together with a co-investor
- Venture & Growth:
- Start-ups and scale-ups: EBITDA EUR <1m
- Cash flow negative (in an accelerated growth scenario)
- Revenue EUR 0 – 5m
What to expect from us?
- Flexible approach to transaction structures: We strive to adapt each structure to the needs of the company and its shareholders. Depending on the type of investment, Holland Capital either provides growth capital and/or acquires existing shares. We are flexible regarding the final capital structure: both majority and minority stakes are possible.
- Deal certainty and an efficient process: Thanks to our sector expertise, we are able to quickly assess a business model and put a fair price on the table. Since the partnership with the entrepreneur and/or the management team is the cornerstone of our investment, we devote above-average attention to ensuring the process is completed efficiently, in the right spirit, and with mutual respect for both parties.
- Transparency towards advisors: We appreciate it when advisors involve us early in discussions with entrepreneurs and/or management teams. In such cases, we always ensure that the advisor’s interests are well safeguarded throughout the process. The advisor retains the flexibility to decide whether to represent the sell-side or buy-side in a potential transaction.
About Holland Capital
Holland Capital has been responsibly and successfully investing in promising Dutch and German SMEs with growth ambitions for over 40 years. The team understands entrepreneurship and fosters an open, sustainable, and professional relationship with the management teams of the invested companies, aiming for mutual growth. With offices in Amsterdam and Düsseldorf, Holland Capital focuses on Healthcare, Technology, and Agrifood-Tech sector.
Holland Capital investeert in Health IT-bedrijf Open HealthHub
Amsterdam, 26 juli 2022 – Holland Capital investeert in Open HealthHub, een digitaal platform waarmee zorgverleners en patiënten veilig en vertrouwd medische gegevens kunnen uitwisselen om administratieve lasten voor zorgverleners te verminderen. De investering wordt...
Holland Capital invests in Health IT company Open HealthHub
Amsterdam, 26 July 2022 – Holland Capital is investing in Open HealthHub, a digital platform that allows healthcare providers and patients to exchange medical data safely and securely. It will also reduce the administrative burden on healthcare providers. The...
Mauritskliniek intends to join Corius
Amsterdam, 21 July 2022 – Our portfolio company Mauritskliniek intends to join Corius. Mauritskliniek provides healthcare services in dermatology, varicose veins, proctology, skin therapy and medical-cosmetic care. The Mauritskliniek is located in Amsterdam, The...
Mauritskliniek is voornemens zich aan te sluiten bij Corius
Amsterdam, 21 juli 2022 – Onze deelneming Mauritskliniek is voornemens zich aan te sluiten bij Corius. Mauritskliniek (incl. Kliniek Veldhoven) is als keten van focusklinieken gerenommeerd voor zorg op het gebied van dermatologie, flebologie (spataderzorg),...
Holland Capital wielerteam trotseert één van Europa’s meest extreme wielerevents
Holland Capital wielerteam trotseert één van Europa’s meest extreme wielerevents Amsterdam, 14 juli 2022 – Een vijftal fanatieke fietsers uit het Holland Capital wielerteam hebben een geweldige prestatie geleverd door één van de meest extreme wielerevents van Europa...
Holland Capital realizes successful exit of Humeca to i4hi
Holland Capital realizes successful exit of Humeca to i4hi Borne / Amsterdam, 5 July 2022 – Investment company Holland Capital realizes a successful exit of Humeca to fellow investor i4hi. Humeca is a leading supplier of innovative products in the field of advanced...
Amsterdam
Krijn Taconiskade 426
1087 HW Amsterdam
+31 (0) 20 3119411
Düsseldorf
Königsallee 42
40212 Düsseldorf
+49 (0) 211 96290120
Contact
info@hollandcapital.nl

